Syndax Pharmaceuticals Stock Performance
| SNDX Stock | USD 19.31 0.41 2.08% |
The entity has a beta of 1.98, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Syndax Pharmaceuticals will likely underperform. At this point, Syndax Pharmaceuticals has a negative expected return of -0.3%. Please make sure to validate Syndax Pharmaceuticals' jensen alpha and daily balance of power , to decide if Syndax Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Syndax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in July 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.13 | Five Day Return 4.17 | Year To Date Return (9.79) | Ten Year Return 64.33 | All Time Return 64.33 |
1 | Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum | 04/10/2024 |
2 | Acquisition by Peter Ordentlich of 90000 shares of Syndax Pharmaceuticals at 28.55 subject to Rule 16b-3 | 04/26/2024 |
3 | Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors | 05/07/2024 |
4 | Syndax Q1 Earnings Snapshot | 05/08/2024 |
5 | Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference | 05/09/2024 |
6 | Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its RD Committee | 05/14/2024 |
7 | Syndax appoints Aleksandra Rizo to board of directors | 05/15/2024 |
8 | Why Ooma Shares Are Trading Higher By Around 17 Here Are 20 Stocks Moving Premarket | 05/29/2024 |
9 | Acquisition by Jarrett Jennifer of 17000 shares of Syndax Pharmaceuticals subject to Rule 16b-3 | 05/31/2024 |
10 | Syndax advances trial for colorectal cancer therapy | 06/06/2024 |
11 | Pyxis Oncology adds biopharma veteran to board | 06/10/2024 |
| Begin Period Cash Flow | 74.5 M |
Syndax |
Syndax Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,376 in Syndax Pharmaceuticals on March 13, 2024 and sell it today you would lose (445.00) from holding Syndax Pharmaceuticals or give up 18.73% of portfolio value over 90 days. Syndax Pharmaceuticals is currently does not generate positive expected returns and assumes 2.5776% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Syndax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Syndax Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Syndax Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Syndax Pharmaceuticals, and traders can use it to determine the average amount a Syndax Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1148
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SNDX |
Estimated Market Risk
| 2.58 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Syndax Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Syndax Pharmaceuticals by adding Syndax Pharmaceuticals to a well-diversified portfolio.
Syndax Pharmaceuticals Fundamentals Growth
Syndax Stock prices reflect investors' perceptions of the future prospects and financial health of Syndax Pharmaceuticals, and Syndax Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Syndax Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 1.22 B | ||||
| Shares Outstanding | 84.99 M | ||||
| Price To Earning | 126.11 X | ||||
| Price To Book | 3.33 X | ||||
| Price To Sales | 12.67 X | ||||
| Gross Profit | 139.71 M | ||||
| EBITDA | (229.94 M) | ||||
| Net Income | (209.36 M) | ||||
| Cash And Equivalents | 350.71 M | ||||
| Cash Per Share | 5.82 X | ||||
| Total Debt | 1.64 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 17.19 X | ||||
| Book Value Per Share | 5.79 X | ||||
| Cash Flow From Operations | (160.6 M) | ||||
| Earnings Per Share | (3.24) X | ||||
| Market Capitalization | 1.64 B | ||||
| Total Asset | 612.88 M | ||||
| Retained Earnings | (902.4 M) | ||||
| Working Capital | 522.78 M | ||||
| Current Asset | 79.72 M | ||||
| Current Liabilities | 13.32 M | ||||
About Syndax Pharmaceuticals Performance
To evaluate Syndax Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Syndax Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Syndax Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Syndax Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Syndax's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 60.9 K | 64 K | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.41) | (0.44) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.38) | (0.40) |
Things to note about Syndax Pharmaceuticals performance evaluation
Checking the ongoing alerts about Syndax Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Syndax Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Syndax Pharmaceuticals generated a negative expected return over the last 90 days | |
| Net Loss for the year was (209.36 M) with profit before overhead, payroll, taxes, and interest of 139.71 M. | |
| Syndax Pharmaceuticals currently holds about 350.71 M in cash with (160.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82. | |
| Syndax Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Pyxis Oncology adds biopharma veteran to board |
- Analyzing Syndax Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Syndax Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Syndax Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Syndax Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Syndax Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Syndax Pharmaceuticals' stock. These opinions can provide insight into Syndax Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.